CanVirex AG
PrivateMomentum
Top 50%
of companies Caplight tracks
Company Overview
CanVirex AG operates in Healthcare & Life Sciences and is based in Basel. It was founded in 2017.
CanVirex AG is a biotechnology company that develops immuno-viro-therapeutic platforms by arming oncolytic measles viruses with immunomodulators for the treatment of cancer and infectious diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
CanVirex AG Comparables
Compare CanVirex AG with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Oncovita | 92% | |
| Theolytics | 82% | |
| ImmVirx | 80% |
For institutional investors. Book with your work email.
CanVirex AG Funding Rounds
Historical fundraising activity
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 76% MoM, reaching 4K.
- May 15, 2026
Monthly visitors increased 238% MoM, reaching 2K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 25, 2026
On Sep 25th '26, CanVirex AG is developing an oncolytic measles virus platform designed to destroy tumors directly while activating a local immune response, as Recipharm transfers its Vero cell/measles virus process in Germany to support scalable production for future clinical studies and potential commercial use.
For institutional investors. Book with your work email.
CanVirex AG Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about CanVirex AG's valuation, stock price, and market status.
Is CanVirex AG a public or private company?
CanVirex AG is a private company.
What is the current stock price of CanVirex AG?
CanVirex AG is a private company, so its shares have no public market price. Caplight tracks CanVirex AG's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is CanVirex AG worth (valuation)?
Valuation information for CanVirex AG is not publicly available.
Can I buy CanVirex AG stock?
CanVirex AG shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was CanVirex AG's last funding round?
Funding round information for CanVirex AG is not publicly available.
Who are the main investors in CanVirex AG?
Investor information for CanVirex AG is not publicly disclosed.
Will CanVirex AG IPO soon?
No public IPO plans have been announced for CanVirex AG.
How can I track CanVirex AG secondary market activity?
Caplight tracks bids, offers, and trades in CanVirex AG's shares on secondary markets.